Guangzhou Magpie Pharmaceuticals Co., Ltd.
Wednesday, June 05, 2024
Company Presentation
![CNS/Neurological](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 4
Guangzhou Magpie Pharmaceuticals Co., Ltd. (MPI) is a leading biotech company in Guangzhou, China with a robust pipeline of late-stage clinical assets. MPI focuses on developing novel treatments for cerebro-cardiovascular, neurodegenerative, and mitochondrial dysfunction diseases, as well as diabetic kidney disease. Currently MPI has 7 new NCEs in development: 3 phase III, 6 phase II, and 1 phase I clinical stage assets in China; and 2 phase I-ready assets in the US.
![Guangzhou Magpie Pharmaceuticals Co., Ltd.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1697822-1-JPG.png)
Company Website:
https://www.magpiepharma.com/
Lead Product in Development:
TBN, MN-08
Company HQ City
Guangzhou
Company HQ State
Guangdong Province
Company HQ Country
China
CEO/Top Company Official
Yuqiang Wang
Development Phase of Primary Product
Phase II
Primary Speaker